Weight loss drug users may need to scal.
The Food and Drug Administration threatens the solution to enabling the brand name of Semaglutide, OZEMPIC, and Zepbound, the brand name of TIRZEPATIDE, so that the patient can access the cheaper alternative while the patient lacks. there is.
Complex pharmacies have produced these brand versions from special allowances due to the lack of FDA approval drugs.
After the FDA declared a shortage, this flexibility was canceled, and the drug complex and the remote medical company Scramble to find the solution Continue sales.
The grace period for producing and selling complex Tir J Paid ended in March. Thursday was the final cutoff of the composite semagluide.
The drug imitates GLP-1 (hormones that are naturally generated after the body) feels richer for a longer richer.
that Outsourcing Facility AssociationThe trading group representing the complex pharmacy filed an impatience of the FDA’s decision in the court, but the judge supported the authority of the agency to enforce the ban.
Such movements are expected to strengthen the supply of these drugs, and the cost of patients relying on a lower composite version is expected to increase.
“A patient who can combine the drug today for $ 350 a month will not have a choice to pay $ 1,000 a month for Mounjaro or Zepbound.
“Simply put, Tir fade will be a cheap amount overnight for many people who rely on it.”
A 53-year-old Spicer pointed out that he attempted all weight loss drugs. “GLP-1 was truly a game changer.” So he believes that this ban will have a great influence on him.
“More than 12% of American adults have used GLP-1 drugs to manage chronic diseases including diabetes, heart disease and obesity.”
The Wall Street Journal reported this week Complex pharmacies and remote health companies have changed how to add some modified doses, vitamins, or to keep drugs to continue selling drugs.
They claim that the law allows personalized drugs, interpretation. Pharmaceutical company. Almost definitely the challenge will come.
The FDA crackdown aims to solve safety issues related to complex drugs, which does not receive the same strict approval process as the brand response.
Remarks of remote health companies, which do not fully evaluate patients or do not disclose potential side effects, add to concern.
However, many experts believe that this is more important than the health benefits of GLP-1, which is cheaper because the United States is in the middle of obesity infectious diseases.
Dr. DISHA NARANG, an endeavor Health’s endocrine scholar and obesity medical officer, said, “The tribe is much better. The scope of insurance is much worse. I told CNN.
“From a practical point of view, patients can’t get employer benefits for medication, and now almost 50% of our country can be potentially qualified. Therefore, it is a strange time to justify the insurance company that obesity is chronic disease.”
